

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Please amend the claims as follows:

1. (Original) Oral pharmaceutical formulation in the form of a granulate comprising more than 60% by weight of mesalazine or a pharmaceutically acceptable salt thereof.
2. (Original) Pharmaceutical formulation according to claim 1 comprising more than 70% by weight of mesalazine or a pharmaceutically acceptable salt thereof.
3. (Original) Pharmaceutical formulation according to claim 1 comprising more than 80% by weight of mesalazine or a pharmaceutically acceptable salt thereof.
4. (Currently Amended) Pharmaceutical formulation according to claim 1 ~~any of the preceding claims~~, having in vitro release characteristics of mesalazine of at least 40% released after 240 min, of the total amount of mesalazine in the formulation, measured in a model system using a USP Paddle System 2 operated at 37°C with stirring at 100 rpm.
5. (Currently Amended) Pharmaceutical formulation according to claim 1 ~~any of the preceding claims~~, having in vitro release characteristics of mesalazine of
 - a) 5 - 25 % released after 15 min;
 - b) 30 - 70 %, preferably 40 - 60 %, released after 90 min; and

c) 75 - 100 % released after 240 min;
of the total amount of mesalazine in the formulation
measured in a model system using a USP Paddle System
2 operated at 37°C with stirring at 100 rpm.

6. (Currently Amended) Pharmaceutical formulation
according to claim 1 ~~any of the preceding claims~~, having
a similarity factor f_2 above 30, preferably above 40, more
preferred above 50, as compared to a standard having the
in vitro release characteristics of mesalazine of

- a) 12 % released after 15 min;
- b) 50 % released after 90 min; and
- c) 85 % released after 240 min;

as measured in a model system using a USP Paddle
System 2 operated at 37°C with stirring at 100 rpm
~~under the conditions of claim 5.~~

7. (Currently Amended) Pharmaceutical formulation
according to claim 1 ~~any of the preceding claims~~, further
comprising a pharmaceutically acceptable binder,
preferably Povidone, in an amount less than or equal to
an amount selected among the group consisting of 1; 2; 3;
4; 5; 6; 7; 8; 9; 10 and 12 % by weight.

8. (Currently Amended) Pharmaceutical formulation
according to claim 1 ~~any of the preceding claims~~, further
comprising a coating, preferably comprising or consisting
of ethylcellulose.

9. (Currently Amended) Pharmaceutical formulation
according to claim 1 ~~any of the preceding claims~~,
comprising a coating, the ratio of the weight of said
coating to the weight of said mesalazine or said

pharmaceutically acceptable salt being selected among 0.1-10%; 0.3-7%; 0.5-5%; 0.7-3%; 0.8-2%; and 0.9-1.5%.

10. (Currently Amended) Pharmaceutical formulation according to claim 1 ~~any of the preceding claims~~, essentially consisting of mesalazine, a pharmaceutically acceptable binder and a coating.

11. (Currently Amended) Pharmaceutical formulation according to claim 1 ~~any of the preceding claims~~, wherein said pharmaceutical formulation is packed in a sachet.

12. (Currently Amended) Method for manufacturing a pharmaceutical formulation according to claim 1 ~~any of the preceding claims~~, comprising the steps:

- a) mixing mesalazine with granulation liquid;
 - b) obtaining granulate by granulating, compacting or extruding;
 - c) drying the granulate;
 - d) adjusting the size of the granulate as necessary; and
 - e) sieving the granulate as necessary;
- characterised in the additional step of:
- f) coating the granulate;
- and optionally further:
- g) sieving the coated granulate;
 - h) air purging the coated granulate.

13. (Original) Method according to claim 12, wherein said coated granulate are packed in a sachet.

14. (Currently Amended) Method according to claim 12 ~~or 13~~, wherein said granulation liquid consists of Povidone dissolved in water.

15. (Currently Amended) Method according to claim 12 ~~any of the claims 12—14~~, wherein said drying step c) is performed in a fluid bed dryer.

16. (Currently Amended) Method according to claim 12 ~~any of the claims 12—15~~, wherein said adjusting of size step d) is performed by milling.

17. (Currently Amended) Method according to claim 12 ~~any of the claims 12—16~~, wherein said sieving step e) is performed by selecting granulate passing a 1.8 mm sieve, but not passing a 0.5 mm sieve.

18. (Currently Amended) Method according to claim 12 ~~any of the claims 12—17~~, wherein said coating step f) is performed with ethylcellulose.

19. (Currently Amended) Method according to claim 12 ~~any of the claims 12—18~~, wherein said coating step f) is performed by applying an amount of coating material adjusted, according to the specific surface area, to be in the range 0.09 - 0.17 mg/cm², preferably 0.11 - 0.15 mg/cm², followed by drying.

20. (Currently Amended) Method according to claim 12 ~~any of the claims 12—19~~, wherein said sieving step g) is performed on a rotation sieve, preferably with a mesh size of 2.5 mm.

21. (Currently Amended) Use of mesalazine for the manufacture of a pharmaceutical formulation according to claim 1 ~~any of the claims 1—11~~, comprising a total dosage amount of mesalazine chosen among the group

consisting of 0,5 g; 1,0 g; 1,5 g; 2 g; 3 g; 4 g; 5 g; 6 g; 8 g; and 10 g; preferably packed in a sachet.

22. (Currently Amended) Use according to claim 21 ~~the preceding claim~~, wherein the medicament is for the treatment of intestinal bowel disease, preferably Crohns's Disease or Ulcerative Colitis.